Search
Henagliflozin
go.drugbank.com/drugs/DB11939InvestigationalHenagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalGlasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … [A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsGadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.
Categories: Compounds used in a research, industrial, or household settingTelotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET.
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsUlimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility … of the GI tract is severely impaired.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … a first-line treatment option in advanced ALK-positive NSCLC.
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g. … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesProducts: XOSPATA® FILM-COATED TABLETS 40MGGepirone
go.drugbank.com/drugs/DB12184Approvedside effects as that of the placebo. … Gepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring